Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290677 · ClinicalTrials.gov registry record · NA
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03290677: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03290677 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290677, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research study is studying cryoablation (a treatment to kill cancer cells with extreme cold) combined with continued treatment with current immune checkpoint inhibitor as a possible treatment for lung cancer.
Interventions
- PROCEDURE Biopsy
- PROCEDURE Cryoablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2023-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03290677
The ClinicalTrials.gov registry entry for NCT03290677 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biopsy is the first listed.
NCT03290677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03290677 about?
NCT03290677 is a clinical study titled "Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy". This research study is studying cryoablation (a treatment to kill cancer cells with extreme cold) combined with continued treatment with current immune checkpoint inhibitor as a possible treatment for lung cancer.
What is the current status of trial NCT03290677?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-01-17. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT03290677?
The interventions under investigation include: Biopsy (PROCEDURE), Cryoablation (PROCEDURE).
Who is sponsoring clinical trial NCT03290677?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.